Patrick Daly
Patrick Daly is a contributing writer for Cancer Nursing Today. He is an assistant editor for DocWire News with several years of experience in producing multimedia content for B2B and B2C audiences in the financial and health care industries.
Articles by Patrick Daly
Different radiotherapy doses in allogeneic HCT conditioning had no apparent impact on the rate of acute GVHD.
Authors observed that ocular graft-versus-host disease usually developed after a history of systemic disease.
A study found fecal microbiome dysbiosis accompanied the onset of gastrointestinal graft-versus-host disease.
BCG vaccination at birth was associated with increased risk of acute GVHD after HCT in pediatric patients.
Vitamin D Deficiency before HSCT was associated with increased rate of aGVHD in patients with thalassemia major.
Higher tacrolimus pharmacokinetic variability had a greater risk of aGVHD that rose alongside concentration variability.
defibrotide added to standard-of-care graft-versus-host disease prophylaxis appeared to improve the rate of acute GVHD.
FEV1/FVC and PEF/pred could identify patients with higher risk for pulmonary chronic graft-versus-host disease before HSCT.
Real-world data showed that ruxolitinib was effective in a population of heavily pretreated patients with cGVHD.
Vedolizumab was safe and effective for GI aGVHD treatment, although its efficacy as GVHD prophylaxis was unclear.
Patients reported significant symptom burden and daily activity impairments in the online Living With Chronic GVHD Patient Su
Researchers found bronchiolitis obliterans syndrome was less frequent in HCT with HID donors compared with MSD and MUDs.
Researchers found sVCAM-1 levels were higher pre- and post-HCT in patients who developed severe aGVHD.
Extracellular vesicles at engraftment in hematopoietic cell transplantation may be a feasible biomarker for acute GVHD.
Patients with steroid-refractory acute graft-versus-host disease who received ECP had better survival than those who did not.
Investigators found greater risk for severe acute graft-versus-host disease in omitting the day 11 dose of mini-methotrexate.
Mocravimod, a S1PR modulator, showed manageable safety and promising efficacy in GVHD.
Leukapheresis was able to collect and store cells from patients with graft-versus-host disease for use in future trials.
Vitamin D receptor deficiency appeared to play a major role in the pathology of gastrointestinal graft-versus-host disease.
Reduced bone marrow mesenchymal stromal cells predicted the development of acute graft-versus-host disease.
670 Madison Ave.
Manalapan, NJ 07726